Major pathway of imipramine metabolism is catalyzed by cytochromes P- 450 1A2 and P-450 3A4 in human liver

A Lemoine, JC Gautier, D Azoulay, L Kiffel, C Belloc, FP Guengerich, P Maurel, P Beaune and JP Leroux

Unite INSERM 75, CHU NECKER, Paris, France.

The metabolism of imipramine by human liver microsomes was examined using a combination of five strategies. Human hepatic microsomes produced N-desmethylimipramine (84%), 2-hydroxyimipramine (10%), and 10- hydroxyimipramine (6%). Preincubation of human hepatocytes in culture with beta-naphthoflavone and macrolides exclusively induced the formation of desmethylimpramine (552%, p < 0.05, and 234%, p < 0.003, respectively). Correlations were obtained between rates of imipramine demethylation and cytochrome P-450 (P-450) 1A2 (r = 0.88, p < 0.001) and P-450 3A (r = 0.80, p < 0.02) concentrations in human liver microsomal preparations from 13 different subjects. Anti-P-450 1A2 and anti-P-450 3A antibodies selectively inhibited N-demethylation (80% and 60%, respectively). N-Demethylation was completely inhibited when anti- 1A2 and anti-3A were added simultaneously. Kinetic studies with human microsomes confirm the contribution of two different enzymes in the N- demethylation. The Km of 1A2 was similar to the high affinity Km in human liver microsomes, whereas the Km of 3A was similar to the low affinity Km in human liver microsomes. P-450 1A2 was apparently more efficient than 3A4 (lower Km and higher Vmax) but was expressed in much lower concentration. Human P-450s 1A2 and 3A4 expressed in yeast efficiently produced desmethylimipramine. These results suggest that P- 450 1A2 and P-450 3A4 are the major enzymes involved in imipramine N- demethylation in human hepatic microsomes. Similar experiments were conducted using P-450 2D6, and they confirmed that P-450 2D6 catalyzes imipramine 2-hydroxylation. Interindividual variations in 3A4 hepatic content may explain the large variations in imipramine blood levels observed after uniform dosages and thus may explain the variations in clinical efficacy. Caution might be advised in the clinical use of tricyclic antidepressants when drugs are also administered that induce or inhibit P-450s 3A4 and 1A2.

Volume 43, Issue 5, pp. 827-832, 05/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				K. Kim, J. A. Johnson, and H. Derendorf Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms J. Clin. Pharmacol., October 1, 2004; 44(10): 1083 - 1105. [Abstract] [Full Text] [PDF]

				T. D. Bjornsson, J. A. Wagner, S. R. Donahue, D. Harper, A. Karim, M. S. Khouri, W. R. Murphy, K. Roman, D. Schneck, D. S. Sonnichsen, et al. A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness J. Clin. Pharmacol., September 1, 2003; 43(9): 943 - 967. [Abstract] [Full Text] [PDF]

				J.-G. Shin, J.-Y. Park, M.-J. Kim, J.-H. Shon, Y.-R. Yoon, I.-J. Cha, S.-S. Lee, S.-W. Oh, S.-W. Kim, and D. A. Flockhart Inhibitory Effects of Tricyclic Antidepressants (TCAs) on Human Cytochrome P450 Enzymes in Vitro: Mechanism of Drug Interaction between TCAs and Phenytoin Drug Metab. Dispos., October 1, 2002; 30(10): 1102 - 1107. [Abstract] [Full Text] [PDF]

				T. K. H. Chang, J. Chen, and W. B. K. Lee Differential Inhibition and Inactivation of Human CYP1 Enzymes by trans-Resveratrol: Evidence for Mechanism-Based Inactivation of CYP1A2 J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 874 - 882. [Abstract] [Full Text] [PDF]

				H. H. Thijssen, J.-P. Flinois, and P. H. Beaune Cytochrome P4502C9 Is the Principal Catalyst of Racemic Acenocoumarol Hydroxylation Reactions in Human Liver Microsomes Drug Metab. Dispos., November 1, 2000; 28(11): 1284 - 1290. [Abstract] [Full Text]

				H. Chen, M. R. Brzezinski, A. G. Fantel, and M. R. Juchau Catalysis of Drug Oxidation during Embryogenesis in Human Hepatic Tissues using Imipramine as a Model Substrate Drug Metab. Dispos., November 1, 1999; 27(11): 1306 - 1308. [Abstract] [Full Text]

				T. L. Nielsen, B. B. Rasmussen, J.-P. Flinois, P. Beaune, and K. Brøsen In Vitro Metabolism of Quinidine: The (3S)-3-Hydroxylation of Quinidine Is a Specific Marker Reaction for Cytochrome P-4503A4 Activity in Human Liver Microsomes J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 31 - 37. [Abstract] [Full Text]

				M. W. Linder and P. E. Keck Jr. Standards of laboratory practice: antidepressant drug monitoring Clin. Chem., May 1, 1998; 44(5): 1073 - 1084. [Abstract] [Full Text] [PDF]

				R. B. van Breemen, D. Nikolic, and J. L. Bolton Metabolic Screening Using On-Line Ultrafiltration Mass Spectrometry Drug Metab. Dispos., February 1, 1998; 26(2): 85 - 90. [Abstract] [Full Text]

				R. S. Obach Nonspecific Binding to Microsomes: Impact on Scale-Up of in Vitro Intrinsic Clearance to Hepatic Clearance as Assessed Through Examination of Warfarin, Imipramine, and Propranolol Drug Metab. Dispos., December 1, 1997; 25(12): 1359 - 1369. [Abstract] [Full Text]

				J. H. Lin and A. Y. H. Lu Role of Pharmacokinetics and Metabolism in Drug Discovery and Development Pharmacol. Rev., December 1, 1997; 49(4): 403 - 449. [Abstract] [Full Text] [PDF]

				G.-J. Sanderink, B. Bournique, J. Stevens, M. Petry, and M. Martinet Involvement of Human CYP1A Isoenzymes in the Metabolism and Drug Interactions of Riluzole In Vitro J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1465 - 1472. [Abstract] [Full Text]

				O. V. Olesen and K. Linnet Hydroxylation and Demethylation of the Tricyclic Antidepressant Nortriptyline by cDNA-Expressed Human Cytochrome P-450 Isozymes Drug Metab. Dispos., June 1, 1997; 25(6): 740 - 744. [Abstract] [Full Text]

				E. Koyama, K. Chiba, M. Tani, and T. Ishizaki J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1199 - 1210. [Abstract] [Full Text]